Media coverage about Ra Pharmaceuticals (NASDAQ:RARX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.7097289510548 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of research firms recently issued reports on RARX. Zacks Investment Research lowered Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. ValuEngine cut Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. BMO Capital Markets cut their price target on Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating on the stock in a research note on Thursday, March 15th. SunTrust Banks restated a “buy” rating on shares of Ra Pharmaceuticals in a research note on Thursday, March 15th. Finally, Royal Bank of Canada restated a “buy” rating and issued a $18.00 price target on shares of Ra Pharmaceuticals in a research note on Tuesday, December 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $19.50.
RARX stock traded down $0.14 during trading on Friday, reaching $5.85. The company’s stock had a trading volume of 254,275 shares, compared to its average volume of 360,677. Ra Pharmaceuticals has a one year low of $5.80 and a one year high of $27.84. The firm has a market capitalization of $193.40, a PE ratio of -2.43 and a beta of 2.05.
In other news, major shareholder Ra Capital Healthcare Fund Lp bought 2,500,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were acquired at an average price of $6.00 per share, for a total transaction of $15,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Enterprise Associates 13 L. New bought 2,000,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were purchased at an average price of $6.00 per share, for a total transaction of $12,000,000.00. The disclosure for this purchase can be found here. 14.50% of the stock is owned by company insiders.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.